Reaction
Weight Gain Poor reporting signals
As of the last recalculation, Weight Gain Poor appears in 2,283 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 42.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 61 | 42.4 | 42.6 |
| Pancrelipase | 132 | 33.0 | 33.1 |
| Palivizumab | 49 | 29.7 | 29.8 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 38 | 28.2 | 28.3 |
| Lumacaftor And Ivacaftor | 20 | 21.5 | 21.5 |
| Asfotase Alfa | 20 | 18.4 | 18.4 |
| Ivacaftor | 14 | 16.2 | 16.2 |
| Dornase Alfa | 34 | 16.0 | 16.1 |
| Zidovudine | 20 | 13.7 | 13.8 |
| Clobazam | 35 | 13.3 | 13.3 |
| Atomoxetine Hydrochloride | 31 | 12.0 | 12.0 |
| Cholestyramine | 14 | 10.6 | 10.6 |
| Lisdexamfetamine Dimesylate | 34 | 9.5 | 9.5 |
| Abacavir Sulfate | 10 | 9.4 | 9.4 |
| Guanfacine | 8 | 9.3 | 9.3 |
| Methylphenidate Hydrochloride | 59 | 9.3 | 9.3 |
| Nevirapine | 8 | 8.1 | 8.1 |
| Dronabinol | 7 | 8.0 | 8.0 |
| Phenytoin | 16 | 7.0 | 7.0 |
| Amikacin | 13 | 7.0 | 7.0 |
| Tobramycin | 18 | 6.9 | 6.9 |
| Ursosiol | 14 | 6.6 | 6.6 |
| Methylphenidate | 20 | 6.3 | 6.3 |
| Tobramycin Solution | 8 | 6.1 | 6.1 |
| Tobramycin Sulfate | 8 | 5.9 | 5.9 |
| Levetiracetam In Sodium Chloride | 45 | 5.4 | 5.4 |
| Levetiracetam Oral | 45 | 5.4 | 5.4 |
| Levetiracetam Injection | 45 | 5.4 | 5.4 |
| Somatropin | 40 | 5.0 | 5.0 |
| Levetiracetam | 71 | 5.0 | 5.0 |
| Cannabidiol | 11 | 4.3 | 4.3 |
| Agalsidase Beta | 4 | 4.0 | 4.0 |
| Cabozantinib | 15 | 2.9 | 2.9 |
| Vigabatrin | 4 | 2.5 | 2.5 |
| Osimertinib | 7 | 2.0 | 2.0 |
| Copper | 4 | 0.8 | 0.8 |